Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 12/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919036 | 0.94 | SRD5A2 (0.54) | SRD5A2PDK2SRD5A1TTRPTPRC | |
| SCHEMBL5846670 | 0.78 | PDK2 (0.55) | SRD5A2PDK2SRD5A1TTRPTPRC | |
| SCHEMBL5847201 | 0.78 | PDK2 (0.55) | SRD5A2PDK2SRD5A1TTRPTPRC | |
| SCHEMBL31151124 | 0.78 | PDK2 (0.55) | SRD5A2PDK2SRD5A1TTRPTPRC | |
| SCHEMBL2456262 | 0.78 | PDK2 (0.55) | SRD5A2PDK2SRD5A1TTRPTPRC | |
| SCHEMBL31146728 | 0.78 | PDK2 (0.55) | SRD5A2PDK2SRD5A1TTRPTPRC | |
| SCHEMBL30673333 | 0.77 | PGR (0.45) | PDK2KMT2A | |
| SCHEMBL29473421 | 0.77 | PGR (0.45) | PDK2KMT2A | |
| SCHEMBL4922107 | 0.77 | PGR (0.45) | PDK2KMT2A | |
| Hydrochloric Acid SCHEMBL5846911 | 0.77 | PDK2 (0.54) | SRD5A2PDK2SRD5A1TTRPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | SRD5A2 3866/4885PDK2 4410/4885SRD5A1 4124/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | SRD5A2 4493/4885PDK2 4775/4885SRD5A1 4556/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | SRD5A2 1526/4885PDK2 4110/4885SRD5A1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.